NDA 018333 · Abbvie
Carafate
Sucralfate · Oral · Aluminum Complex
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Mar 4, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1981
Oct 30, 1981
Approved uses
2
Original approval plus efficacy supplements
Registered trials
26
4 Phase 3, 2 recruiting
FAERS reports
24,155
16,587 serious, 2,328 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 2, 2026.
INDICATIONS AND USAGE Sucralfate is indicated in: • Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. • Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 11, 1990 Supplement 9 · Efficacy
- Oct 30, 1981 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- CARAFATE · SUCRALFATE 1GM · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Sucralfate" as an intervention, any sponsor and status, largest first.
- Comparative Effectiveness of Alginate, Magaldrate, Sucralfate, Proton Pump Inhibitors, and Diet in Laryngopharyngeal Reflux DiseasePivotal-lookingNot yet recruiting
University of MonsAcademic, hospital or other
NCT07611162 · 800 participants (planned) · Start May 1, 2026 · Primary completion May 1, 2030
Drug: Alginate; Magaldrate and 2 more · For: Laryngopharyngeal Reflux Disease
Sites: Mons, Belgium
- A Comparison of Effectiveness of Oral Sucrolfate, Alginate and Hydrotalcide in Dispeptic Pain TreatmentPivotal-lookingCompleted
Pamukkale UniversityAcademic, hospital or other
NCT03635372 · 300 participants · Start Jun 20, 2017 · Primary completion Oct 22, 2017
Drug: Alginate; Sucralfate and 1 more · For: Dyspepsia
Sites: Denizli, Turkey (Türkiye)
- A Study of Chlorophyllin or Placebo With Standard Treatment for Late Radiation Induced Luminal Gastrointestinal Tract BleedingPivotal-lookingNot yet recruiting
Tata Memorial CentreAcademic, hospital or other
NCT07837713 · 200 participants (planned) · Start Sep 15, 2026 · Primary completion Sep 10, 2028
Drug: Chlorophyllin, Sodium Copper Complex; Placebo · For: Radiation Proctitis; Gastrointestinal Hemorrhage; Radiation Injuries
Sites: Mumbai, India
- Colonoscopic Sucralfate Spray in Prevention of Delayed Polypectomy BleedingPivotal-lookingStatus unknown
National Cheng-Kung University HospitalAcademic, hospital or other
NCT05817656 · 160 participants (planned) · Start May 15, 2023 · Primary completion Apr 14, 2024
Drug: Sucralfate · For: Bleeding
Sites: Tainan, Taiwan
- Prevention of Delayed Post-polypectomy Bleeding by Endoscopic Sucralfate Spray in High-risk Patients: A Randomized Controlled TrialPivotal-lookingNot yet recruiting
National Cheng-Kung University HospitalAcademic, hospital or other
NCT07257926 · 160 participants (planned) · Start Dec 15, 2025 · Primary completion Dec 31, 2027
Drug: Sucralfate · For: Bleeding After GI Endoscopy
- A Study to Evaluate the Efficacy of Teprenone On Chinese Patients With Chronic Non-Atrophic Erosive GastritisPivotal-lookingCompleted
Changhai HospitalAcademic, hospital or other
NCT01284647 · 156 participants · Start Feb 2011 · Primary completion Oct 2012
Drug: Teprenone capsule and placebo of sucralfate; Sucralfate and placebo of teprenone · For: Chronic Erosive Gastritis
Sites: Beijing, China; Xiamen, China; Nanning, China · 8 sites in all
- Reducing Acute Upper Gastrointestinal Side-Effects of Thoracic IrradiationPivotal-lookingCompleted
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT05659576 · 142 participants · Start Dec 13, 2022 · Primary completion Aug 26, 2026
Drug: Sucralfate · For: Radiation Esophagitis
Sites: Basking Ridge, New Jersey; Middletown, New Jersey; Montvale, New Jersey · 7 sites in all
- Alginate vs Sucralfate for GERD Symptomatic ReliefPivotal-lookingCompleted
CMH Lahore Medical College and Institute of DentistryAcademic, hospital or other
NCT07310927 · 140 participants · Start Apr 1, 2025 · Primary completion Apr 30, 2026
Drug: Alginate; Sucralfate · For: GERD
Sites: Lahore, Pakistan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea2,389
- fatigue1,831
- diarrhoea1,787
- pain1,543
- headache1,453
- vomiting1,433
- off label use1,386
- dyspnoea1,383
- drug ineffective1,359
- dizziness1,095
- abdominal pain1,035
- weight decreased1,031
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 252 |
| 2005 | 266 |
| 2006 | 251 |
| 2007 | 265 |
| 2008 | 324 |
| 2009 | 405 |
| 2010 | 543 |
| 2011 | 660 |
| 2012 | 880 |
| 2013 | 727 |
| 2014 | 841 |
| 2015 | 1,422 |
| 2016 | 1,829 |
| 2017 | 1,577 |
| 2018 | 1,878 |
| 2019 | 2,058 |
| 2020 | 1,851 |
| 2021 | 1,461 |
| 2022 | 1,358 |
| 2023 | 1,407 |
| 2024 | 1,322 |
| 2025 | 1,509 |
| 2026 | 1,064 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Carafate (Sucralfate)
2024 spending
$1.3M
Beneficiaries
1,372
2,941 claims
Per beneficiary
$917
$1.24 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $28,700,306 |
| 2021 | $6,334,080 |
| 2022 | $3,052,062 |
| 2023 | $2,290,698 |
| 2024 | $1,257,911 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug-induced ulcers and dyspepsia.
Garegnani L, Oltra G, Burgos MA, et al. · Cochrane Database Syst Rev 2025 · Meta-Analysis, Systematic Review
- Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients: systematic review and network meta-analysis.
Wang Y, Ye Z, Ge L, et al. · BMJ 2020 · Research Support, Non-U.S. Gov't, Systematic Review
- Sucralfate--alternative therapy for peptic-ulcer disease.
Garnett WR · Clin Pharm 1982 · Clinical Trial, Review
- Pharmacological interventions for non-ulcer dyspepsia.
Moayyedi P, Soo S, Deeks J, et al. · Cochrane Database Syst Rev 2004 · Meta-Analysis, Systematic Review
- Sucralfate for posttonsillectomy analgesia.
Ozcan M, Altuntaş A, Unal A, et al. · Otolaryngol Head Neck Surg 1998 · Clinical Trial
- Pharmacological interventions for non-ulcer dyspepsia.
Moayyedi P, Soo S, Deeks J, et al. · Cochrane Database Syst Rev 2006 · Meta-Analysis, Systematic Review
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.